MedTrace Logo

Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma

NCT01956695 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2020-12-17

No results posted yet for this study

Summary

Because Primary Central Nervous System Lymphoma (PCNSL) are mainly diffuse large B-cell lymphoma of the activated B cells (ABC) type, the investigators hypothesize that the synergy of lenalidomide with rituximab shown in systemic non-Hodgkin's lymphoma (NHL) could be observed in PCNSL.

This study will assess the efficiency of the the combination of lenalidomide and rituximab in relapsed/refractory PCNSL, and the efficiency of a maintenance treatment with lenalidomide alone in maintaining the response.

Conditions

Interventions

DRUG

Lenalidomide

DRUG

Rituximab

Sponsors & Collaborators

  • Centre Hospitalier Universitaire, Amiens

    collaborator OTHER

  • Institut Bergonié

    collaborator OTHER

  • University Hospital, Clermont-Ferrand

    collaborator OTHER

  • University Hospital, Lille

    collaborator OTHER

  • Central Hospital, Nancy, France

    collaborator OTHER

  • Groupe Hospitalier Pitie-Salpetriere

    collaborator OTHER

  • Centre Henri Becquerel

    collaborator OTHER

  • University Hospital, Tours

    collaborator OTHER

  • Centre Leon Berard

    collaborator OTHER

  • University Hospital, Grenoble

    collaborator OTHER

  • Institut Curie

    lead OTHER

Principal Investigators

  • Carole SOUSSAIN, MD · Institut Curie - Hopital Rene Huguenin

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-18
Primary Completion
2018-01-11
Completion
2018-01-11

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01956695 on ClinicalTrials.gov